[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593285":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":27,"collaborators":7,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":7,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":54},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Jingjing Xu","CONTACT","86 134-260-50924","335418449@qq.com",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":7},"FuWai Hospital","RECRUITING","Beijing","China","CN",{"type":22,"coordinates":23},"Point",[24,25],116.39723,39.9075,{"lat":25,"lon":24},{"type":28,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100593285","multi-modal-adverse-events-prediction-for-premature-coronary-heart-disease-trial-map-chd-trial-100593285",false,"NCT07004452","Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial","Inclusion Criteria:\n\n* Age 18-45 years;\n* Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;\n* For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;\n* Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Heart transplant recipients;\n* Severe systemic comorbidities with life expectancy \\\u003C1 year;\n* Previous enrollment in other drug\u002Fdevice clinical trials without completing the primary endpoint observation period;\n* Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).","ALL","18 Years","45 Years",{"count":39,"type":40},5000,"ESTIMATED","OBSERVATIONAL","The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:\n\n* What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease?\n* What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.",[44],"Premature Coronary Heart Disease","2025-05-27",{"date":47,"type":48},"2025-06-04","ACTUAL",{"date":50,"type":48},"2025-03-31",{"date":52,"type":40},"2027-07",{"name":5,"class":6},1]